Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis

26 Aug 2016

Abstract excerpt

The protozoan parasite Trypanosoma brucei causes the fatal illness human African trypanosomiasis (HAT). Standard of care medications currently used to treat HAT have severe limitations, and there is a need to find new chemical entities that are active against infections of T. brucei. Following a "drug repurposing" approach, we tested anti-trypanosomal effects of carbazole-derived compounds called "Curaxins". In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Research on Leishmaniasis Studies
Share to Synthesis and Biological Evaluation
Share to Trypanosoma species research and implications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27561392
DOI: 10.1038/srep32083

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of a Carbazole-Derived Lead Drug for Human African TrypanosomiasisPMID 27561392Read ↗

A Brief Review of Drug Discovery Research for Human African TrypanosomiasisSemantic proximity Read ↗

The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targetsSemantic proximity Read ↗

Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug DiscoverySemantic proximity Read ↗

A Static-Cidal Assay for Trypanosoma brucei to Aid Hit Prioritisation for Progression into Drug Discovery ProgrammesSemantic proximity Read ↗

The critical role of mode of action studies in kinetoplastid drug discoverySemantic proximity Read ↗

Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against TrypanosomatidsSemantic proximity Read ↗

Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infectionsSemantic proximity Read ↗

Phenotypic profiling of Pathogen Box compounds MMV667494 and MMV028694 in bloodstream-form Trypanosoma brucei brucei.Semantic proximity Read ↗

Identification of clinically approved small molecules that inhibit growth and promote surface remodeling in the African trypanosomeSemantic proximity Read ↗

Discovery of Novel Quinoline-Based Proteasome Inhibitors for Human African Trypanosomiasis (HAT)Semantic proximity Read ↗

Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library.Semantic proximity Read ↗

Design, Synthesis and Biological Evaluation of Trypanosoma brucei Trypanothione Synthetase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.